1. Home
  2. CANF vs SURG Comparison

CANF vs SURG Comparison

Compare CANF & SURG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$3.37

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Logo SurgePays Inc.

SURG

SurgePays Inc.

HOLD

Current Price

$0.17

Market Cap

6.4M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CANF
SURG
Founded
1994
2006
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.7M
6.4M
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
CANF
SURG
Price
$3.37
$0.17
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$50.00
$5.00
AVG Volume (30 Days)
21.6K
14.0M
Earning Date
03-26-2026
04-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
24.69
EPS
N/A
N/A
Revenue
N/A
$56,962,920.00
Revenue This Year
$2,715,455.50
$136.77
Revenue Next Year
$101.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.15
52 Week High
$10.40
$3.14

Technical Indicators

Market Signals
Indicator
CANF
SURG
Relative Strength Index (RSI) 50.19 33.04
Support Level $3.18 N/A
Resistance Level $3.60 $0.41
Average True Range (ATR) 0.14 0.05
MACD 0.00 -0.00
Stochastic Oscillator 39.02 5.94

Price Performance

Historical Comparison
CANF
SURG

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

About SURG SurgePays Inc.

Surgepays Inc is a wireless and point of sale technology company focused on serving underserved and value-conscious consumers through a combination of retail distribution and digital acquisition channels. It provides mobile connectivity, financial technology services, and transaction processing solutions through an integrated platform that combines wireless services with point of sale software and retail distribution. It enables in-store and online activation of wireless services, prepaid top-ups, and financial transactions, allowing consumers to access essential services in both local and digital environments. Its segments are wireless services or MVNO Telecommunications, platform services or MVNE Enablement Platform (HERO), and wholesale enablement or Comprehensive Platform Services.

Share on Social Networks: